ADA- and ETN-treated AS patients (n = 31) | ETN-treated AS patients (n = 15) | ADA-treated AS patients (n = 16) | |
---|---|---|---|
Demographics | |||
Sex (M:F) | 22:9 | 11:4 | 11:5 |
Age (years) | 38 ± 10.2 | 37.7 ± 11.5 | 38.3 ± 9.2 |
Disease status | |||
DD (months) | 140.8 ± 117.9 | 145.1 ± 135.4 | 136.8 ± 103.8 |
BASDAI at baseline | 6.2 ± 1.3 | 6.2 ± 1.5 | 6.2 ± 1.2 |
BASDAI red. (%) | 47.6 ± 31.3 | 51.1 ± 31.7 | 44.3 ± 31.6 |
BASDAI assessment (months) | 3.1 ± 1.4 | 3 ± 1 | 3.2 ± 1.6 |
BASDAI50 (R:NR) | 19:12 | 10:5 | 9:7 |
CRP (mg/dl) | 1.5 ± 1.7 | 1.3 ± 1.1 | 1.6 ± 2.2 |
HLA-B27-positive (%) | 81 | 87 | 75 |
ESR (mm/h) | 33.2 ± 21.9 | 31.7 ± 22.3 | 34.6 ± 22.3 |